Daxiang Pharmaceutical

Company Profile of Hubei Daxiang Pharmaceutical Co., Ltd.
Introduction of Hubei BeatriXMer Medical Technical Co., Ltd.

Hubei Daxiang Pharmaceutical Co., Ltd. (hereinafter referred to as "Daxiang"), headquartered in Wuhan, Hubei, is a pharmaceutical GSP wholesale enterprise. The company also has a medical device GSP wholesale enterprise, Hubei Beiximei Medical Technology Co., Ltd. (hereinafter referred to as "Beiximei"). Its business scope covers provincial-level agency and national platform construction in multiple fields such as prescription drugs, retail, and medical aesthetics. Through strategic cooperation with major commercial channels, it extends professional academic promotion and marketing planning services to terminals across various regions. After years of rapid development, the company has grown into a large pharmaceutical enterprise with assets exceeding 100 million yuan and more than 100 employees. The company's three major business segments are: Prescription Drug Business Unit, Retail Business Unit, and Medical Aesthetics Business Unit.
1. Prescription Drug Business Unit (RX): In collaboration with well-known pharmaceutical companies such as Xi'an Xingfu, Yunnan Sailing, Chengdu Beite, Yunnan Botanee, Hefei Yifan, Guizhou Weikang Zifan, Shenzhen Dafo, and Sandoz (China), it has established a professional promotion team covering nearly 2,000 tertiary and grassroots hospitals in Hubei and Henan in fields such as oncology, hepatology, orthopedics, gynecology, and pediatrics, with multiple products achieving top sales in tertiary hospitals. In terms of commercial distribution, the company has formed deep strategic cooperation with major commercial systems such as Sinopharm, China Resources, Jointown, Neptunus, Chongqing Pharmaceutical, and Nanjing Pharmaceutical, and has extensive cooperation with more than 300 pharmaceutical distribution enterprises in various cities across the two provinces, covering target hospitals in Hubei and Henan. The company possesses professional solutions in "market access," "development capability," "academic capability," and "sales capability."
2. Retail Business Unit (MR): In 2017, the company established a retail marketing team covering the entire Hubei province, forming a business layout primarily based on direct sales, and successfully created a marketing model of new retail of prescription drugs + golden single products, forming strategic partnerships with many well-known chain enterprises in Hubei (Hubei Laobaixing Chain, Hubei Yifeng Chain, Hubei Tianji Chain). In the future, the Retail Business Unit will expand its business territory and build a health service system in Central China.
3. Medical Aesthetics Business Unit (EM): Mainly engaged in medical aesthetics business. Over the past two years, the company's agency brands such as "Tongyan," "Jelly Needle," Galderma series, Huaxi series, Korean Letybo botulinum toxin, and Austrian Princess hyaluronic acid and other outstanding brands in the industry have held thousands of academic conferences in major medical aesthetics institutions in Hubei and Henan, repeatedly setting off marketing storms sweeping the medical aesthetics industry in Hubei and Henan.

Daxiang Pharmaceutical will take "serving the industry with products, creating the future with services" as its philosophy, adhere to the business purpose of "caring for human health," promote the vigorous development of the pharmaceutical and health industry, and contribute to the great rejuvenation of the Chinese nation.